Titre:	Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach
Auteur(s):	Cruz, Rossilene Conceição da Silva Bührer-Sékula, Samira Penna, Gerson Oliveira Moraes, Maria Elisabete Amaral de Gonçalves, Heitor de Sá Stefani, Mariane Martins de Araújo Penna, Maria Lúcia Fernandes Pontes, Maria Araci de Andrade Talhari, Sinésio
Assunto::	Drogas Hanseníase Terapêutica
Date de publication:	2018
Editeur:	Sociedade Brasileira de Dermatologia
Référence bibliographique:	CRUZ, Rossilene Conceição da Silva et al. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach. Anais Brasileiros de Dermatologia, Rio de Janeiro, v. 93, n. 3, p. 377-384, maio/jun. 2018. DOI: http://dx.doi.org/10.1590/abd1806-4841.20186709. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000300377&lng=en&nrm=iso. Acesso em: 12 abr. 2019.
Abstract:	BACKGROUND: The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR), designed to evaluate the effectiveness of a six-months regimen, assessed the adverse effects caused by the drugs. OBJECTIVE: Describe adverse effects due to MDT in U-MDT/CT-BR, comparing the uniform regimen (U-MDT) to the current WHO regimen (R-MDT). Patients and methods: After operational classification, patients were randomly allocated to the study groups. U-MDT PB and U-MDT MB groups, received the U-MDT regimen, six doses of MB-MDT (rifampicin, dapsone and clofazimine). R-MDT PB and R-MDT MB groups, received the WHO regimens: six doses (rifampicin and dapsone) for PB and 12 doses (rifampicin, dapsone and clofazimine) for MB. During treatment, patients returned monthly for clinical and laboratorial evaluation. Patients with single lesion were not included in this trial. RESULTS: Skin pigmentation (21.7%) and xerosis (16.9%) were the most frequent complaints among 753 patients. Laboratory exams showed hemoglobin concentration lower than 10g/dL in 23.3% of the patients, glutamic oxaloacetic transaminase (GOT) above 40U/L in 29.5% and glutamic pyruvic transaminase (GPT) above 40U/L in 28.5%. Twenty-four patients (3.2%) stopped dapsone intake due to adverse effects, of whom 16.6% due to severe anemia. One case of sulfone syndrome was reported. STUDY LIMITATIONS: Loss of some monthly laboratory sample collection. CONCLUSIONS: There was no statistical difference regarding adverse effects in the R-MDT and U-MDT groups but anemia was greater in patients from R-MDT/MB group, therefore adverse effects do not represent a constraint to recommend the six-month uniform regimen of treatment for all leprosy patients.
metadata.dc.description.unidade:	Faculdade de Medicina (FMD)
Licença::	Anais Brasileiros de Dermatologia - (CC BY NC) - This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial License which permits unrestricted noncommercial use, distribution, and reproduction in any medium provided the original work is properly cited. Fonte: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000300377&lng=en&nrm=iso. Acesso em: 12 abr. 2019.
DOI:	http://dx.doi.org/10.1590/abd1806-4841.20186709
Collection(s) :	Artigos publicados em periódicos e afins

Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.